Proactive Investors - Run By Investors For Investors

eWellness Healthcare targeting $7 billion injury-prevention industry via sales, marketing

From 2013 to 2018, Occupational Health and Workplace Safety Services industry revenue increased at an annualized rate of 2.3%
health
The California-based company, which has operations in the US and Canada, offers the PHZIO telemedicine platform

eWellness Healthcare Corporation (OTCQB:EWLL), the physical therapy telehealth company, announced Friday that it is targeting the $7 billion injury-prevention industry through sales and marketing.

The company noted that, according to business-information provider IBISWorld, the Occupational Health and Workplace Safety Services industry in the US provides advice and assistance in the form of worksite evaluations, compliance audits, hazard assessments, facility-design reviews, indoor air-quality evaluations and training programs.

From 2013 and 2018, industry revenue increased at an annualized rate of 2.3% to $7.1 billion.

Following Friday’s announcement, the company’s stock jumped 31% to $0.07 on the OTC Markets.

READ: eWellness Healthcare doubles down on $4 billion North American musculoskeletal treatment market

The Culver City, California-based company, which has operations in the US and Canada, offers the PHZIO telemedicine platform.

eWellness says its PHZIO platform allows patients and physical therapists to “cut the cord from the old-school, wait in line, brick and mortar clinical experience” to an “immediate response,” digital in-home physical therapy experience.

The company offers insurance-reimbursable, real-time, distance-monitored treatments.

The company’s PHZIO platform lowers treatment costs, expands treatment access and improves patient compliance.

eWellness says that at least 80% of all physical therapy assessments and treatments can now be done via a patient’s smartphone.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

View full EWLL profile View Profile

eWellness Healthcare Corp. Timeline

Related Articles

microscope
April 30 2019
The health sciences company has five research and development programs, including gene therapy, its Sol-gel program for nose-to-brain delivery of medical compounds including cannabinoids, as well as non-addictive analgesic peptides as a replacement for morphine, fentanyl and oxycodone
Nemaura Medical Inc CEO Dr Faz Chowdhury
November 05 2018
The medtech company is eying explosive growth with sugarBEAT, on the cusp of launching in the UK, followed by the rest of Europe in 2018
pills
April 12 2019
The biotechnology company is developing a platform of unique drugs designed to prevent serious gastrointestinal damage and bleeding caused by chronic naproxen use
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use